Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

GameChanger Law Advisors advised Peptris Technologies on its licensing agreement with Revio Therapeutics for PEPR124 (RT001), ...

The money is developing treatments for diabetes, cancer and Alzheimer's disease. It could also mean a cure for a Ridgefield ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...

Shirley MacFarland’s weekly community column featuring news and notes from Brecksville, Broadview Heights, North Royalton and ...

U.S. Sen. Richard Blumenthal and researchers raise the alarm on how a federal medical research funding cap could impact "life ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Thinking her little boy had trouble with balance when he started to have minor falls Kelly took William to see a pediatrician ...